The GLP-1 medication multidistrict litigation (MDL), involving Ozempic, Wegovy, and Mounjaro, has reached an important stage with the filing of a Master Complaint
Most are mild to moderate, but some patients may need to discontinue treatment
The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis
Looking through the NPDS coding book, a moderate effect is described as follows: The patient exhibited symptoms as a result of the exposure which are more pronounced, more prolonged or more of a systemic nature than minor symptoms
However, these drugs have side effects, including gastrointestinal upset and nausea
The main difference is that tablets tend to cause more digestive sensitivity, while injections are more associated with mild injection-site reactions